

Erika Peverelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4514013/publications.pdf>

Version: 2024-02-01

58
papers

1,635
citations

279798

23
h-index

302126

39
g-index

60
all docs

60
docs citations

60
times ranked

3774
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 1 | Pituitary Tumors: Genetic and Molecular Factors Underlying Pathogenesis and Clinical Behavior. <i>Neuroendocrinology</i> , 2022, 112, 15-33. | 2.5 | 16 |
| 2 | Somatostatin receptors regulation in corticotroph tumors: the role of cytoskeleton and USP8 mutations. <i>Endocrine Oncology</i> , 2022, , . | 0.4 | 0 |
| 3 | P720R USP8 Mutation Is Associated with a Better Responsiveness to Pasireotide in ACTH-Secreting PitNETs. <i>Cancers</i> , 2022, 14, 2455. | 3.7 | 3 |
| 4 | DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells. <i>Frontiers in Endocrinology</i> , 2022, 13, . | 3.5 | 3 |
| 5 | Beta-Arrestin 2 Is Required for Dopamine Receptor Type 2 Inhibitory Effects on AKT Phosphorylation and Cell Proliferation in Pituitary Tumors. <i>Neuroendocrinology</i> , 2021, 111, 568-579. | 2.5 | 9 |
| 6 | The cytoskeleton actin binding protein filamin A impairs both IGF2 mitogenic effects and the efficacy of IGF1R inhibitors in adrenocortical cancer cells. <i>Cancer Letters</i> , 2021, 497, 77-88. | 7.2 | 7 |
| 7 | Octreotide and pasireotide effects on medullary thyroid carcinoma (MTC) cells growth, migration and invasion. <i>Molecular and Cellular Endocrinology</i> , 2021, 520, 111092. | 3.2 | 4 |
| 8 | GNAS, McCuneâ€Albright syndrome, and GH-producing tumors. , 2021, , 197-223. | | 0 |
| 9 | Filamin A is required for somatostatin receptor type 5 expression and pasireotide-mediated signaling in pituitary corticotroph tumor cells. <i>Molecular and Cellular Endocrinology</i> , 2021, 524, 111159. | 3.2 | 5 |
| 10 | Drug resistance in pituitary tumours: from cell membrane to intracellular signalling. <i>Nature Reviews Endocrinology</i> , 2021, 17, 560-571. | 9.6 | 8 |
| 11 | Genetic Profiling of a Cohort of Italian Patients with ACTH-Secreting Pituitary Tumors and Characterization of a Novel USP8 Gene Variant. <i>Cancers</i> , 2021, 13, 4022. | 3.7 | 11 |
| 12 | Cytoskeleton Protein Filamin A Is Required for Efficient Somatostatin Receptor Type 2 Internalization and Recycling through Rab5 and Rab4 Sorting Endosomes in Tumor Somatotroph Cells. <i>Neuroendocrinology</i> , 2020, 110, 642-652. | 2.5 | 13 |
| 13 | A Novel Mechanism Regulating Dopamine Receptor Type 2 Signal Transduction in Pituitary Tumoral Cells: The Role of cAMP/PKA-Induced Filamin A Phosphorylation. <i>Frontiers in Endocrinology</i> , 2020, 11, 611752. | 3.5 | 7 |
| 14 | Cofilin is a mediator of RET-promoted medullary thyroid carcinoma cell migration, invasion and proliferation. <i>Molecular and Cellular Endocrinology</i> , 2019, 495, 110519. | 3.2 | 5 |
| 15 | Stem Cells in Pituitary Tumors: Experimental Evidence Supporting Their Existence and Their Role in Tumor Clinical Behavior. <i>Frontiers in Endocrinology</i> , 2019, 10, 745. | 3.5 | 9 |
| 16 | Somatostatin analogs regulate tumor corticotrophs growth by reducing ERK1/2 activity. <i>Molecular and Cellular Endocrinology</i> , 2019, 483, 31-38. | 3.2 | 14 |
| 17 | Cytoskeleton actin-binding proteins in clinical behavior of pituitary tumors. <i>Endocrine-Related Cancer</i> , 2019, 26, R95-R108. | 3.1 | 14 |
| 18 | A novel pathway activated by somatostatin receptor type 2 (SST2): Inhibition of pituitary tumor cell migration and invasion through cytoskeleton protein recruitment. <i>International Journal of Cancer</i> , 2018, 142, 1842-1852. | 5.1 | 22 |

| # | ARTICLE | IF | CITATIONS |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 19 | Single-Molecule Microscopy Reveals Dynamic FLNA Interactions Governing SSTR2 Clustering and Internalization. <i>Endocrinology</i> , 2018, 159, 2953-2965. | 2.8 | 22 |
| 20 | cAMP/PKA-induced filamin A (FLNA) phosphorylation inhibits SST2 signal transduction in GH-secreting pituitary tumor cells. <i>Cancer Letters</i> , 2018, 435, 101-109. | 7.2 | 21 |
| 21 | Dopamine receptor type 2 (<scp>DRD2</scp>) and somatostatin receptor type 2 (<scp>SSTR2</scp>) agonists are effective in inhibiting proliferation of progenitor/stemâ€like cells isolated from nonfunctioning pituitary tumors. <i>International Journal of Cancer</i> , 2017, 140, 1870-1880. | 5.1 | 54 |
| 22 | Cofilin is a cAMP effector in mediating actin cytoskeleton reorganization and steroidogenesis in mouse and human adrenocortical tumor cells. <i>Cancer Letters</i> , 2017, 406, 54-63. | 7.2 | 8 |
| 23 | Somatostatin Receptor Type 2 (SSTR2) Internalization and Intracellular Trafficking in Pituitary GH-Secreting Adenomas: Role of Scaffold Proteins and Implications for Pharmacological Resistance. <i>Hormone and Metabolic Research</i> , 2017, 49, 259-268. | 1.5 | 7 |
| 24 | Identification of human somatostatin receptor 2 domains involved in internalization and signaling in QGP-1 pancreatic neuroendocrine tumor cell line. <i>Endocrine</i> , 2017, 56, 146-157. | 2.3 | 12 |
| 25 | Dopamine receptor type 2 (DRD2) inhibits migration and invasion of human tumorous pituitary cells through ROCK-mediated cofilin inactivation. <i>Cancer Letters</i> , 2016, 381, 279-286. | 7.2 | 33 |
| 26 | Expression of protein kinase A regulatory subunits in benign and malignant human thyroid tissues: A systematic review. <i>Experimental Cell Research</i> , 2016, 346, 85-90. | 2.6 | 7 |
| 27 | Filamin-A is required to mediate SST2 effects in pancreatic neuroendocrine tumours. <i>Endocrine-Related Cancer</i> , 2016, 23, 181-190. | 3.1 | 18 |
| 28 | Landscape of somatic mutations in sporadic GH-secreting pituitary adenomas. <i>European Journal of Endocrinology</i> , 2016, 174, 363-372. | 3.7 | 100 |
| 29 | Dopamine and Somatostatin Analogues Resistance of Pituitary Tumors: Focus on Cytoskeleton Involvement. <i>Frontiers in Endocrinology</i> , 2015, 6, 187. | 3.5 | 28 |
| 30 | cAMP effects in neuroendocrine tumors: The role of Epac and PKA in cell proliferation and adhesion. <i>Experimental Cell Research</i> , 2015, 339, 241-251. | 2.6 | 17 |
| 31 | Filamin A in Somatostatin and Dopamine Receptor Regulation in Pituitary and the Role of cAMP/PKA Dependent Phosphorylation. <i>Hormone and Metabolic Research</i> , 2014, 46, 845-853. | 1.5 | 16 |
| 32 | cAMP in the pituitary: an old messenger for multiple signals. <i>Journal of Molecular Endocrinology</i> , 2014, 52, R67-R77. | 2.5 | 52 |
| 33 | Specific roles of Gi protein family members revealed by dissecting SST5 coupling in human pituitary cells. <i>Journal of Cell Science</i> , 2014, 127, 2377-2377. | 2.0 | 0 |
| 34 | Cyclic adenosine 3â€2-5â€2-monophosphate (cAMP) exerts proliferative and anti-proliferative effects in pituitary cells of different types by activating both cAMP-dependent protein kinase A (PKA) and exchange proteins directly activated by cAMP (Epac). <i>Molecular and Cellular Endocrinology</i> , 2014, 383, 193-202. | 3.2 | 35 |
| 35 | Filamin A (FLNA) Plays an Essential Role in Somatostatin Receptor 2 (SST2) Signaling and Stabilization After Agonist Stimulation in Human and Rat Somatotroph Tumor Cells. <i>Endocrinology</i> , 2014, 155, 2932-2941. | 2.8 | 40 |
| 36 | Quantitative Analysis of Methylation Defects and Correlation With Clinical Characteristics in Patients With Pseudohypoparathyroidism Type I and GNAS Epigenetic Alterations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E508-E517. | 3.6 | 49 |

| # | ARTICLE | IF | CITATIONS |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 37 | Autosomal Dominant Pseudohypoparathyroidism Type Ib: A Novel Inherited Deletion Ablating <i>STX16</i> Causes Loss of Imprinting at the A/B DMR. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E724-E728. | 3.6 | 68 |
| 38 | Specific roles of Gi protein family members revealed by dissecting SST5 coupling in human pituitary cells. <i>Journal of Cell Science</i> , 2013, 126, 638-644. | 2.0 | 24 |
| 39 | PKA regulatory subunit R2B is required for murine and human adipocyte differentiation. <i>Endocrine Connections</i> , 2013, 2, 196-207. | 1.9 | 14 |
| 40 | Deciphering the specific role of G \pm i/o isoforms: functional selective oxytocin ligands and somatostatin SST5 receptor mutants. <i>Biochemical Society Transactions</i> , 2013, 41, 166-171. | 3.4 | 5 |
| 41 | Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations. <i>Endocrine-Related Cancer</i> , 2013, 20, 753-766. | 3.1 | 50 |
| 42 | Filamin-A Is Essential for Dopamine D2 Receptor Expression and Signaling in Tumorous Lactotrophs. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 967-977. | 3.6 | 55 |
| 43 | Macroautophagy and the proteasome are differently involved in the degradation of alpha-synuclein wild type and mutated A30P in an in vitro inducible model (PC12/TetOn). <i>Neuroscience</i> , 2011, 195, 128-137. | 2.3 | 26 |
| 44 | Evolution of an Aggressive Prolactinoma into a Growth Hormone Secreting Pituitary Tumor Coincident with <i>GNAS</i> Gene Mutation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 13-17. | 3.6 | 45 |
| 45 | The dopamine-somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways. <i>Cancer Letters</i> , 2010, 288, 170-176. | 7.2 | 49 |
| 46 | Pseudohypoparathyroidism and <i>GNAS</i> Epigenetic Defects: Clinical Evaluation of Albright Hereditary Osteodystrophy and Molecular Analysis in 40 Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 651-658. | 3.6 | 144 |
| 47 | Characterization of Intracellular Signaling Mediated by Human Somatostatin Receptor 5: Role of the DRY Motif and the Third Intracellular Loop. <i>Endocrinology</i> , 2009, 150, 3169-3176. | 2.8 | 29 |
| 48 | Analysis of genetic variants of phosphodiesterase 11A in acromegalic patients. <i>European Journal of Endocrinology</i> , 2009, 161, 687-694. | 3.7 | 21 |
| 49 | Peripheral insulin-like factor 3 concentrations are reduced in men with type 2 diabetes mellitus: effect of glycemic control and visceral adiposity on Leydig cell function. <i>European Journal of Endocrinology</i> , 2009, 161, 853-859. | 3.7 | 23 |
| 50 | High expression of PKA regulatory subunit 1A protein is related to proliferation of human melanoma cells. <i>Oncogene</i> , 2008, 27, 1834-1843. | 5.9 | 40 |
| 51 | Different expression of protein kinase A (PKA) regulatory subunits in cortisol-secreting adrenocortical tumors: Relationship with cell proliferation. <i>Experimental Cell Research</i> , 2008, 314, 123-130. | 2.6 | 32 |
| 52 | The Third Intracellular Loop of the Human Somatostatin Receptor 5 Is Crucial for Arrestin Binding and Receptor Internalization after Somatostatin Stimulation. <i>Molecular Endocrinology</i> , 2008, 22, 676-688. | 3.7 | 39 |
| 53 | HESX1 expression in human normal pituitaries and pituitary adenomas. <i>Molecular and Cellular Endocrinology</i> , 2006, 247, 135-139. | 3.2 | 12 |
| 54 | Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. <i>Endocrine-Related Cancer</i> , 2006, 13, 955-962. | 3.1 | 92 |

| # | ARTICLE | IF | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 55 | Effect of Cyclic Adenosine 3'5'-Monophosphate/Protein Kinase A Pathway on Markers of Cell Proliferation in Nonfunctioning Pituitary Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 6721-6724. | 3.6 | 32 |
| 56 | Expression of the two alternatively spliced PRKAR1A RNAs in human endocrine glands. <i>Molecular and Cellular Endocrinology</i> , 2005, 238, 51-55. | 3.2 | 1 |
| 57 | Proliferation of Transformed Somatotroph Cells Related to Low or Absent Expression of Protein Kinase A Regulatory Subunit 1A Protein. <i>Cancer Research</i> , 2004, 64, 9193-9198. | 0.9 | 88 |
| 58 | Protective effect of TATA α -delivered β -synuclein: relevance of the C-terminal domain and involvement of HSP70. <i>FASEB Journal</i> , 2004, 18, 1713-1715. | 0.5 | 77 |